The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform

Oncology (Williston Park). 2021 Sep 15;35(9):553-559. doi: 10.46883/ONC.2021.3509.0553.

Authors

Kristen Ciombor¹, Jeremy Jones², John Strickler³, Tanios Bekaii-Saab⁴, Christina Wu⁵

Affiliations

¹ Division of Hematology/Oncology, Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
² Mayo Clinic, Jacksonville, FL, USA.
³ Duke University Medical Center, Durham, North Carolina, USA.
⁴ Mayo Clinic, Scottsdale, AZ, USA.
⁵ Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.

PMID: 34524770
DOI: 10.46883/ONC.2021.3509.0553

No abstract available

MeSH terms

Brain Neoplasms
Colorectal Neoplasms / drug therapy
Colorectal Neoplasms / genetics*
ErbB Receptors / antagonists & inhibitors
High-Throughput Nucleotide Sequencing
Humans
Liquid Biopsy
Microsatellite Instability
Mutation
Neoplastic Syndromes, Hereditary
Proto-Oncogene Proteins p21(ras) / genetics
Receptor, ErbB-2 / genetics

Substances

KRAS protein, human
ERBB2 protein, human
ErbB Receptors
Receptor, ErbB-2
Proto-Oncogene Proteins p21(ras)

Supplementary concepts

Turcot syndrome